Literature DB >> 29106886

Surgical Treatment for Early Small Cell Lung Cancer: Variability in Practice and Impact on Survival.

Elliot Wakeam1, James P Byrne2, Gail E Darling3, Thomas K Varghese4.   

Abstract

BACKGROUND: Surgical resection with lobectomy is recommended for T1/T2 N0 small cell lung cancer (SCLC) patients after negative mediastinal staging. We sought to characterize variation in surgical therapy for early SCLC and determine the effect of a hospital's practice patterns on patient survival.
METHODS: The National Cancer Database was examined from 2004 to 2013. Risk- and reliability-adjusted hierarchical logistic regression was used to estimate the adjusted odds of resection by hospital. Hospitals were then grouped into quartiles by observed-to-expected rates of surgical treatment. Patient, tumor, and hospital characteristics were compared across quartiles. Kaplan-Meier plots and Cox proportional hazard models were built to compare patient survival as a function of a hospital's tendency to use surgical intervention.
RESULTS: We identified 5,079 patients with T1/T2 N0 SCLC in 317 hospitals, and 1,260 underwent resection. Analysis after adjusting for demographic, comorbidity, and tumor factors showed patients treated at hospitals in the highest quartile of surgical use were 17 times more likely to undergo surgical resection than those in the lowest quartile (44.8% vs 7.6%; odds ratio, 16.7l; 95% confidence interval, 12.59 to 22.18). Hospitals in the highest quartile were more likely to be academic centers (48% vs 21%), more likely to perform lobectomy (28.3% vs 5.0%), and treated more mixed-histology tumors (11.1% vs 4.5%). Survival was significantly longer for patients treated at hospitals most likely to use surgical therapy (median, 25.3 vs. 18.8 months; p < 0.0001). Hazard ratio differences in mortality persisted in multivariate Cox models (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.89; p < 0.0001).
CONCLUSIONS: Large variation exists in the use of surgical therapy for early SCLC in the United States, which may represent a significant quality improvement opportunity for patients with early SCLC.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29106886     DOI: 10.1016/j.athoracsur.2017.07.009

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Comparing Treatment Strategies for Stage I Small-cell lung Cancer.

Authors:  Peter Paximadis; Jennifer L Beebe-Dimmer; Julie George; Anne G Schwartz; Antoinette Wozniak; Shirish Gadgeel
Journal:  Clin Lung Cancer       Date:  2018-03-23       Impact factor: 4.785

Review 2.  Endobronchial ultrasound-transbronchial needle aspiration (EBUS/TBNA): a diagnostic challenge for mediastinal lesions.

Authors:  Duilio Divisi; Gino Zaccagna; Mirko Barone; Francesca Gabriele; Roberto Crisci
Journal:  Ann Transl Med       Date:  2018-03

3.  The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer.

Authors:  Vignesh Raman; Oliver K Jawitz; Chi-Fu Jeffrey Yang; Soraya L Voigt; Thomas A D'Amico; David H Harpole; Betty C Tong
Journal:  J Thorac Cardiovasc Surg       Date:  2020-03-22       Impact factor: 5.209

Review 4.  The current role of surgery and SBRT in early stage of small cell lung cancer.

Authors:  Núria Farré; José Belda-Sanchis; Mauro Guarino; Laura Tilea; Jady Vivian Rojas Cordero; Elisabeth Martínez-Téllez
Journal:  J Clin Transl Res       Date:  2021-02-17

Review 5.  New perspectives in the management of small cell lung cancer.

Authors:  Cristina Pangua; Jacobo Rogado; Gloria Serrano-Montero; José Belda-Sanchís; Beatriz Álvarez Rodríguez; Laura Torrado; Nuria Rodríguez De Dios; Xabier Mielgo-Rubio; Juan Carlos Trujillo; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-06-24

6.  The extent of mediastinal lymph node dissection correlates with survival of small cell lung cancer patients after resection: a propensity score-matched cohort study analysis.

Authors:  Jinlin Cao; Jinming Xu; Haojie Yu; Pengxu Qian; Wang Lv; Tianyu He; Ping Yuan; Filippo Longo; Luca Bertolaccini; Kazuhiro Yasufuku; A Justin Rucker; Jian Hu
Journal:  Transl Lung Cancer Res       Date:  2022-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.